Greenstone stands apart through pioneering iPSC NAMs expertise, a powerful synergy of human-relevant models and AI, and a visionary team with decades of scientific and industry experience.
Backed by Leading Life Science Investors and Strategic Partners
Greenstone Biosciences is a venture-backed, platform-driven biotech poised at the forefront of innovation in drug discovery and development. Our leadership is anchored by a team with deep roots in induced pluripotent stem cell (iPSC) technology and disease modeling—an origin that has shaped our reputation as the go-to experts in New Approach Methods (NAMs).
Our Mission & Platform
We harness the power of iPSC-derived NAMs, computational chemistry, and AI-enhanced drug design, alongside rigorous ADME-Tox (ADMeT) assessments, to create a streamlined and predictive drug development pipeline. This integrated platform uniquely positions us to efficiently transition promising candidates from discovery into clinical evaluation.
Our Pipeline
Advance & Focused: We currently have two lead programs progressing toward clinical trials.
Strategic Validation: Both candidates exemplify the robustness of our NAM- and AI-backed platform—moving forward with strong preclinical data and translational readiness.
Investment Opportunity
Greenstone Biosciences is currently inviting conversations with institutional investors, strategic partners, and vision-aligned capital. We are seeking to expand our financial foundation to accelerate our current clinical-stage pipelines and scale our platform capabilities.
Contact us to explore investment opportunities and learn more about our emerging leadership in NAM- and AI-integrated drug development.